Dementia poses a major health challenge with no safe, affordable treatments to slow its progression. Researchers at Lawson ...

A landmark study by London researchers investigating the use of a cough medicine called Ambroxo to slow the progression of ...

Semaglutide — the active ingredient in type 2 diabetes and weight-loss glucagon-like peptide-1 agonist ( GLP-1) medications ...

A new study from UCLA Health has uncovered how inflammation in brain blood vessels exacerbates damage in vascular dementia ...

A new study from UCLA Health has uncovered how inflammation in brain blood vessels exacerbates damage in vascular dementia ...

The active ingredient in Ozempic was associated with a reduced risk of Alzheimer's disease-related dementia among diabetes ...

A groundbreaking analysis from leading British universities has uncovered surprising links between everyday medications and ...

Semaglutide is linked to a reduced risk for Alzheimer’s disease-related dementia in patients with diabetes vs other antidiabetic drugs, a new study suggests.

Beyond helping diabetes patients lose weight and control blood sugar, semaglutide appears to cut dementia risk by nearly half ...

A 12-month clinical trial investigated whether a cough medicine used in Europe called Ambroxol can slow dementia in people with Parkinson’s.

The study, carried out by experts from the University of Nottingham and funded by the National Institute for Health Research ...

Researchers at the Case Western Reserve School of Medicine have found that semaglutide, a popular diabetes and weight-loss drug, may lower the risk of dementia in people with type 2 diabetes ...